Treatment of Knee Osteoarthritis with Intraarticular Umbilical Cord-Derived Wharton’s Jelly: A Case Report

We present the case of a 27-year-old male with grade II knee osteoarthritis (OA) that was intraarticularly injected with a 2 mL umbilical cord-derived Wharton’s jelly (UC-derived WJ) formulation. The patients’ baseline radiographs were taken and baseline numeric pain rating scale (NPRS), knee injury...

Full description

Saved in:
Bibliographic Details
Published inPharmaceuticals (Basel, Switzerland) Vol. 14; no. 9; p. 883
Main Authors Gupta, Ashim, Rodriguez, Hugo C., Potty, Anish G., Levy, Howard J., El-Amin III, Saadiq F.
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.09.2021
MDPI
Subjects
Arthritis
biologics
Blood vessels
Cartilage
Case Report
Case reports
Cell division
exosomes
Growth factors
Hyaluronic acid
Inflammation
Knee
knee osteoarthritis
Laboratories
Likert scale
Osteoarthritis
Pain
Pathophysiology
Patients
Quality of life
regenerative medicine
Steroids
Umbilical cord
Wharton’s jelly
X-rays
United States > US
Online AccessGet full text

Cover

More Information
Summary:We present the case of a 27-year-old male with grade II knee osteoarthritis (OA) that was intraarticularly injected with a 2 mL umbilical cord-derived Wharton’s jelly (UC-derived WJ) formulation. The patients’ baseline radiographs were taken and baseline numeric pain rating scale (NPRS), knee injury and osteoarthritis outcome score (KOOS), 7-point Likert scale, and a 36-item short form survey (SF-36) were recorded. The NPRS was re-recorded immediately after the injection, and at 24 h, 48 h, 1 week, 6 weeks, and at 3 months follow-up post-injection. The KOOS and 7-point Likert scale was re-recorded at the patients’ 1week, 6 week, and 3month follow-up, and SF-36 was re-recorded at 3 months. A final set of X-rays were also performed at 3 months follow-up post-injection. No adverse effects from the injection were reported over the duration of the study. No significant difference nor progression in OA on X-rays compared to baseline was observed. NPRS decreased by 50% and the 7-point Likert scale increased to Extremely Satisfied. KOOS increased overall by 10% and the SF-36 overall change was 25%. These results indicate the potential application of UC-derived WJ in the treatment of knee OA. Larger, long term, non-randomized and randomized control trials are warranted to adequately assess the safety and efficacy of UC-derived WJ and ultimate clinical use.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph14090883